Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 57

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 57
---
 to the term of another patent that is commonly owned or
names a common inventor. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly
uncertain.

Our competitors may be able
to circumvent our owned or any future in-licensed patents by developing similar or alternative technologies or products in a non-infringing
manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and future in-licensed patents
may be challenged in the courts or patent offices in the United States and abroad. For example, we may become involved in opposition,
interference, derivation, inter partesreview or other proceedings challenging our patent rights, and the outcome of any proceedings
are highly uncertain. Such challenges may result in the patent claims of our owned or any future in-licensed patents being narrowed, invalidated
or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar
or identical technology and products, or limit the duration of the patent protection of our technology and products.

In addition, given the amount
of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient
rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our patents and patent applications
are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners’
interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including
our competitors, and our competitors could market competing products and technology. In addition, we or our future licensors may need
the cooperation of any such co-owners of our owned and in-licensed patents in order to enforce such patents against third parties, and
such cooperation may not be provided to us or our future licensors. Any of the foregoing could have a material adverse effect on our competitive
position, business, financial conditions, results of operations and prospects.

Patent terms may be inadequate to protect
our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan.
In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally